The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

7 Nov 2013 07:00

RNS Number : 4049S
Sopheon PLC
07 November 2013
 



SOPHEON PLC

("Sopheon" or the "Company")

 

INTERIM MANAGEMENT STATEMENT

 

Sopheon plc, the international provider of software and services that improve the financial return from innovation and new product development investments, issues its interim management statement for the period since 1 July 2013 to date.

 

In our interim report issued at the end of August, we reported an improvement in half year results over our solid 2012 performance, with revenues for the half year of £6.6m (2012: £6.2m) and revenue visibility for 2013 of £10.5m. Visibility today stands at £11.9m compared to £11.7m a year ago.  Meeting our commercial goals will require a strong finish to the year, and we are working to close several sales opportunities from new and existing clients to achieve this objective. As we always emphasize, our revenues are sensitive to the timing and value of individual orders.

 

We have some exciting activities and events underway in the second half of the year. We are participating in major innovation conferences for the Chemical, Food & Beverage, and Personal Care industries and have also launched a new Chemical industry webinar series. We are also participating in over a dozen other events, webinars and roundtables. Later this month we launch Accolade Release 9.0. This release introduces a new Accolade Roadmapping module, superseding Vision Strategist, an updated release of Idea Lab, and many other valuable additions and enhancements. Our third release in 2013, this reflects a fast pace of development that underpins our market position and is enabled by the Agile methodology we have adopted. Looking further ahead, we are working on a completely new website which will launch in early 2014 and will further enhance our marketing capabilities for reaching and engaging with buyers globally.

 

During the summer we implemented the first phase of the corporate restructuring. This was implemented through a two-step process involving a 10,000:1 share consolidation followed by a 1:500 share subdivision one week later. This procedure reduced the number of shares in issue by a ratio of 20, from 145.6 million shares to 7.3 million shares. It also reduced the number of shareholders on the Company's UK share register from approximately 4,000 to just over 200. This does not include shareholders in the Dutch system, which we expected to fall from over 7,000 to under 2,000. As previously noted, we have received indications that the reduction was not correctly processed by certain brokers in the Netherlands. We believe this means the Dutch shareholder count may have reduced to around 5,000. We continue to make appropriate enquiries and representations in the Netherlands, and the board will consider its options in light of the responses received. We are now working on the second phase of our restructuring, the elimination of the accumulated deficit on the profit and loss account, and expect to complete this by the end of the year.

 

A definition of how visibility is calculated was provided in our half- yearly report published on 21 August 2013. 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Josh Royston / Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAPFKEAFDFFF
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.